{"id":963,"date":"2015-11-25T08:37:34","date_gmt":"2015-11-25T08:37:34","guid":{"rendered":"http:\/\/www.enyopharma.com\/fr\/?p=963"},"modified":"2016-03-17T17:49:39","modified_gmt":"2016-03-17T17:49:39","slug":"enyo-pharma-se-renforce-dans-lhepatite-b","status":"publish","type":"post","link":"https:\/\/www.enyopharma.com\/fr\/enyo-pharma-se-renforce-dans-lhepatite-b\/","title":{"rendered":"91天堂 se renforce dans l\u2019h\u00e9patite B"},"content":{"rendered":"<p>Lyon, le 25 novembre 2015. 91天堂, soci\u00e9t\u00e9 biopharmaceutique centr\u00e9e sur le traitement des infections virales aigu\u00ebs et chroniques, annonce avoir pris une licence sur un brevet cl\u00e9 permettant l\u2019exploitation des mol\u00e9cules agonistes du r\u00e9cepteur farneso\u00efde (FXR) comme traitements contre l\u2019h\u00e9patite B.<\/p>\n <a href=\"http:\/\/www.enyopharma.com\/wp-content\/uploads\/2016\/02\/PR-Enyo-30-novembre-2015-FR.pdf\"rel=\"\" target=\"_blank\" target=\"_blank\" class=\"tano-file\"><span class=\"tano_download_icon\"><\/span><span class=\"tano_file_title\">T\u00e9l\u00e9charger le communiqu\u00e9 complet (PDF)<\/span><\/a>\u00a0\n","protected":false},"excerpt":{"rendered":"<p>Lyon, le 25 novembre 2015. 91天堂, soci\u00e9t\u00e9 biopharmaceutique centr\u00e9e sur le traitement des infections virales aigu\u00ebs et chroniques, annonce avoir pris une licence sur un brevet cl\u00e9 permettant l\u2019exploitation des mol\u00e9cules agonistes du r\u00e9cepteur farneso\u00efde (FXR) comme traitements contre l\u2019h\u00e9patite B.<\/p>\n<p><a class=\"read-more\" href=\"https:\/\/www.enyopharma.com\/fr\/enyo-pharma-se-renforce-dans-lhepatite-b\/\">Lire la suite&nbsp;&raquo;<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[17],"tags":[],"class_list":["post-963","post","type-post","status-publish","format-standard","hentry","category-press-releases-fr"],"acf":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","rttpg_featured_image_url":null,"rttpg_author":{"display_name":"admin91天堂91天堂","author_link":"https:\/\/www.enyopharma.com\/fr\/author\/adminenyopharma\/"},"rttpg_comment":0,"rttpg_category":"<a href=\"https:\/\/www.enyopharma.com\/fr\/category\/press-releases-fr\/\" rel=\"category tag\">Press releases<\/a>","rttpg_excerpt":"Lyon, le 25 novembre 2015. 91天堂, soci\u00e9t\u00e9 biopharmaceutique centr\u00e9e sur le traitement des infections virales aigu\u00ebs et chroniques, annonce avoir pris une licence sur un brevet cl\u00e9 permettant l\u2019exploitation des mol\u00e9cules agonistes du r\u00e9cepteur farneso\u00efde (FXR) comme traitements contre l\u2019h\u00e9patite B.Lire la suite&nbsp;&raquo;","_links":{"self":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts\/963","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/comments?post=963"}],"version-history":[{"count":1,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts\/963\/revisions"}],"predecessor-version":[{"id":964,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts\/963\/revisions\/964"}],"wp:attachment":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/media?parent=963"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/categories?post=963"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/tags?post=963"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}